Ken Griffin Point Biopharma Global Inc. Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2023

Nov 14, 2023
BUY
$6.67 - $9.71 $34,017 - $49,521
5,100 Added 130.77%
9,000 $60,000
Q2 2023

Aug 14, 2023
SELL
$6.86 - $10.86 $8,918 - $14,118
-1,300 Reduced 25.0%
3,900 $35,000
Q1 2023

May 15, 2023
BUY
$6.78 - $8.1 $35,256 - $42,120
5,200 New
5,200 $37,000

Others Institutions Holding PNT

# of Institutions
1
Shares Held
20K
Call Options Held
0
Put Options Held
0
View Full List

About POINT Biopharma Global Inc.

PNT Quotes by TradingView
  • Ticker PNT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 104,025,000
  • Description
  • POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...
More about PNT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email